Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−7 JPY
−1.11 B JPY
617.00 M JPY
188.53 M
About SOLASIA PHARMA K K
Sector
Headquarters
Tokyo
Founded
2006
Website
ISIN
JP3436500007
FIGI
BBG00G21HHJ3
Solasia Pharma KK engages in the development, sale, import and export of pharmaceutical products and medical devices. It provides patients access to western oncology and hematology therapies by developing products licensed from western pharmaceutical and biotechnology companies. The company was founded by Bard Geesaman, John McDonald, and Koji Shinozaki in December 2006 and is headquartered in Tokyo, Japan.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 4597 is 40 JPY — it has decreased by −2.38% in the past 24 hours. Watch SOLASIA PHARMA K K stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on TSE exchange SOLASIA PHARMA K K stocks are traded under the ticker 4597.
4597 stock has fallen by −6.82% compared to the previous week, the month change is a −6.82% fall, over the last year SOLASIA PHARMA K K has showed a −27.27% decrease.
We've gathered analysts' opinions on SOLASIA PHARMA K K future price: according to them, 4597 price has a max estimate of 54.00 JPY and a min estimate of 54.00 JPY. Watch 4597 chart and read a more detailed SOLASIA PHARMA K K stock forecast: see what analysts think of SOLASIA PHARMA K K and suggest that you do with its stocks.
4597 reached its all-time high on May 17, 2017 with the price of 652 JPY, and its all-time low was 23 JPY and was reached on Apr 18, 2024. View more price dynamics on 4597 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
4597 stock is 5.00% volatile and has beta coefficient of 0.27. Track SOLASIA PHARMA K K stock price on the chart and check out the list of the most volatile stocks — is SOLASIA PHARMA K K there?
Yes, you can track SOLASIA PHARMA K K financials in yearly and quarterly reports right on TradingView.
SOLASIA PHARMA K K is going to release the next earnings report on Feb 12, 2025. Keep track of upcoming events with our Earnings Calendar.
4597 net income for the last quarter is −260.00 M JPY, while the quarter before that showed −300.00 M JPY of net income which accounts for 13.33% change. Track more SOLASIA PHARMA K K financial stats to get the full picture.
No, 4597 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 23, 2024, the company has 24.00 employees. See our rating of the largest employees — is SOLASIA PHARMA K K on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SOLASIA PHARMA K K EBITDA is −962.00 M JPY, and current EBITDA margin is −103.57%. See more stats in SOLASIA PHARMA K K financial statements.
Like other stocks, 4597 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SOLASIA PHARMA K K stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SOLASIA PHARMA K K technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SOLASIA PHARMA K K stock shows the sell signal. See more of SOLASIA PHARMA K K technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.